Immunosyn is a development stage marketing and distribution company. Our headquarter offices are located in La Jolla, CA, with a regional office in Chicago, IL and a Scientific Advisory Board that is globally positioned. Our first product to be introduced, currently called SF-1019, is believed by our Scientific Advisory Board to be one of a new class of therapeutics made from mammalian cells that may have the ability to dramatically affect many auto-immune, neurological and demyelinating conditions resulting in a rapid reduction of symptoms. SF-1019 will be marketable upon receipt of potential regulatory approval in the appropriate jurisdictions.

 

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). (For more information on Immunosyn and SF- 1019 go to www.immunosyn.com) .

Immunosyn Corporation Official Website

Safe Harbor disclaimer: Certain statements contained herein constitute forward-looking statements within the meaning of Section 27Aof the Securities Act and Section 21E of the Exchange Act. Such statements include, without limitation, statements regarding business and financing plans, business trends and future operating revenues and expenses. Although the company believes that the statements are reasonable, it can give no assurance that such expecta- tions will prove to be correct. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate and similar expressions, or which by their nature refer to future events. The company cautions investors that any forward-looking statements made by the company are not guarantees of future performance, and that the actual results may differ materially from those in the forward-looking statements as a result of vari- ous factors, including but not limited to, the company’s ability to continue its projected growth, or to be able to fully implement its business strategies.

This profile is not without bias, and is a paid release. investingnewsalerts.com has been compensated for dissemination of company information on behalf of a third party. investingnewsalerts.com has been compensated 900,000 shares of stock for coverage of this stock, by a third party, for services provided including dissemination of company information in this release. investingnewsalerts.com holds no shares of the stock. investingnewsalerts.com may receive shares for extension of its services. Any shares will be disclosed at such time that investingnewsalerts.com is aware of a clients desire to extend the original services. investingnewsalerts.com may have received shares of a company profiled in this release prior to the dissemination of the information in this release. investingnewsalerts.com may immediately sell some or any shares in a profiled company held by investingnewsalerts.com and may have previously sold shares in a profiled company held by investingnewsalerts.com. investingnewsalerts.com's services for a company may cause the company's stock price to increase, in which event investornewsalerts.com would make a profit when it sells its stock in a company. In addition, investingnewsalerts.com's selling of a company's stock may have a negative effect on the market price of the stock.

Got question, found problem? - info@investingnewsalerts.com